Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate
EC number: 950-412-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 28-01-2014 to 04-03-2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study performed under GLP. All relevant validity criteria were met.
- Justification for type of information:
- Information as to the availability of the in vivo study is provided in 'attached justification'.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries, Test Data for Registration of Agricultural Chemicals, Acute oral toxicity (2-1-1), 12 Nousan No 8147, Agricultural Production Bureau, November 24, 2000
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- inspected: November 2012; signature: April 2014
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- Reaction mass of (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate
- EC Number:
- 950-412-8
- Molecular formula:
- C16H28O3
- IUPAC Name:
- Reaction mass of (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1RS)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2RS,3RS)-3-ethyloxiran-2-yl]acetate and (1RS)-1-[(1SR)-3,3-dimethylcyclohexyl]ethyl [(2SR,3SR)-3-ethyloxiran-2-yl]acetate
- Test material form:
- liquid
- Details on test material:
- - Physical state: Liquid
- Storage condition of test material: ca. 4°C in the dark under nitrogen
- Other: colourless
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD (SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Recognised supplier
- Females (if applicable) nulliparous and non-pregnant: Yes.
- Age at study initiation: 8 - 12 weeks.
- Weight at study initiation: 198 - 239 g
- Fasting period before study: Overnight before dosing and approximately four hours after dosing.
- Housing: Group housed in groups of up to three same sex in suspended solid-floor polycarbonate cages furnished with softwood flakes and aspen chew block as cage enrichment..
- Diet (e.g. ad libitum): Certified diet from recognised supplier, provided ad libitum (except for fasting period).
- Water (e.g. ad libitum): ad libitum (except for fasting period)
- Acclimation period: At least 5 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 23
- Humidity (%): 40 - 70%
- Air changes (per hr): Not reported. Positive pressure, filtered air environment.
- Photoperiod: 12 h light / 12 h dark
IN-LIFE DATES: From: To: 2014-01-28 to 2014-03-04
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: The test item was formulated at concentrations of 30 or 200 mg/mL in the vehicle and administered at a volume of 10 mL/kg body weight. Formulations were prepared on the day of dosing.
- Amount of vehicle (if gavage): The concentration of the test item in vehicle was varied to allow constant dosage volume in terms of mL/kg body weight.
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed.
- Lot/batch no. (if required): See full study report.
- Purity: See full study report.
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg bw.
DOSAGE PREPARATION (if unusual): Not applicable. The test item was prepared in the vehicle. It was administered to the animals under a volume of 10 mL/kg. The volume administer was adjusted according to bodyweight on day of treatment.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: 300 mg/kg bw based on guideline recommendations. In the absence of data regarding the toxicity of the test item, 300 mg/kg was chosen as the starting dose. - Doses:
- 300 mg/kg bw in corn oil vehicle (starting dose); 2000 mg/kg bw
- No. of animals per sex per dose:
- 3 initial females (sighting study) and further 3 females (main study); total of up to 6 per dose according to sequential guideline testing strategy.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were made 0.5, 1, 2, and 4 hours after dosing and then daily for fourteen days. Morbidity and mortality checks were made twice daily. Individual body weights were recorded on Day 1 (the day of dosing) and on Days 8 and 15.
- Necropsy of survivors performed: yes
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 300 mg/kg bw: No mortality
2000 mg/kg bw: Two females mortalites on day 2 (B12) and 7 (B10) respectively. - Clinical signs:
- other: 300 mg/kg bw: No signs of systemic toxicity were noted. 2000 mg/kg bw: Clinical signs prior to death comprised of piloerection and elevated gait (both B10 and B12), hunched posture (B10) and loose faeces (B12). Surviving female signs comprised salivation,
- Gross pathology:
- 300 mg/kg bw: No abnormalities were noted at necropsy.
2000 mg/kg bw: Macroscopic examination at study termination on Day 15 revealed pallor of the liver and kidneys in one female (B11). No abnormalities were noted at necropsy amongst other survivors.
In the non-survivors: congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, lungs, liver, spleen and kidneys, clear fluid content in the thoracic cavity, pallor of the stomach, small caecum, yellow fluid content in the small intestine and duodenum (both B11 and B12). Enlarged spleen, red fluid content in the duodenum and gaseous distension in the small and large intestine (B10) and yellow fluid content in the stomach, gaseous distension in the duodenum and yellow fluid content in the large intestine (B12) - Other findings:
- - Organ weights: Not reported.
- Histopathology: Not reported. No macropathological abnormalities (coupled with relevant clincial signs) amongst survivors.
- Potential target organs: Not applicable. No macropathological abnormalities (coupled with relevant clincial signs) amongst survivors.
- Other observations: Not applicable.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study the oral LD50 was established to be > 300 and < 2000 mg/kg bw in female Crl:CD (SD) rats.
- Executive summary:
The study was performed according to OECD TG 423, EU Method B.1 tris, US EPA OPPTS 870.1100 and Japan Acute Oral Toxicity (2-1-1) (2000) guidelines in accordance with GLP to assess the acute oral toxicity of the test item by the acute toxic class method following a single oral administration in the female Crl:CD (SD) strain rat. The test item was administered by oral gavage in corn oil vehicle at a dose volume of approximately 10 mL/kg in an initial step at 300 mg/kg in three females. In the absence of significant toxicity, at this dose level the test item was then administered again in a further three females. In the absence of toxicity the test item was finally administered at 2000 mg/kg bw in corn oil by oral gavage to a group of three females. At 300 mg/kg bw there was no mortality, no significant clinical signs and a slight bodyweight loss or low body weight gain was noted between Days 8 and 15 for most females receiving 300 mg/kg/day. As no such effects were seen at 2000 mg/kg/day the minor bodyweight loss in females receiving 300 mg/kg/day was not considered to be related to the treatment. There was no abnormalities at necropsy. At 2000 mg/kg bw, there was two mortalities on day 2 and 7. Clinical signs prior to death comprised of piloerection and elevated gait (both animals), and then loose faeces and hunched posture, respectively. Clinical signs for survivors included salivation, chin rubbing, under activity, piloerection, elevated gait and loose faeces in one female. Recovery, as judged by external appearance and behaviour, was complete by Day 2. All survivors gained bodyweight. Macroscopic examination at study termination on Day 15 revealed pallor of the liver and kidneys in one female. Under the conditions of this study the oral LD50 was established to be > 300 and < 2000 mg/kg bw in the female rat.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.